MedTrace Logo

EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer

NCT00896961 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2013-01-16

No results posted yet for this study

Summary

This laboratory study is using EF5 to evaluate tumor hypoxia in patients with high-grade soft tissue sarcoma or mouth cancer. Using the drug EF5 to measure the oxygen level in tumor cells may help in planning cancer treatment

Conditions

  • Stage I Adult Soft Tissue Sarcoma
  • Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity
  • Stage II Adult Soft Tissue Sarcoma
  • Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity
  • Stage III Adult Soft Tissue Sarcoma
  • Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity

Interventions

DRUG

EF5

OTHER

diagnostic laboratory biomarker analysis

OTHER

pharmacological study

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Stephen Michael Hahn · Abramson Cancer Center at Penn Medicine

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-08-31
Primary Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00896961 on ClinicalTrials.gov